Early Stage Alzheimer’s Clinical Trial
The National Institute on Aging, a branch of the National Institutes of Health, is conducting a clinical trial to test a new drug treatment for people with early- stage Alzheimer’s disease. The drug being studied, Exendin-4 or Exenatide, has already been approved by the Food and Drug Administration (FDA) for the treatment of diabetes. Researchers have found that this medication is able to protect the brain’s neurons (cells that process and transmit information) from damage.
Participants may be eligible for this three-year study if they have been diagnosed with mild cognitive impairment or early-stage dementia or Alzheimer’s disease; are 65 or older; have a caregiver who is able to accompany them on every visit; and who do not have additional neurological or psychiatric disease, history of stroke, or diabetes. Researchers will share clinically significant findings with each patient’s personal physician as well.
The NIA Clinical Research Branch is located on the 5th floor of Harbor Hospital, 3001 South Hanover Street, in South Baltimore. Parking is free.
For more information, please call (410) 350-7395.